Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CABA Cabaletta Bio	$1.87 -2.1%	$1.38	$0.99 ▼ $13.50	$94.89M	2.72	1.56 million shs	1.03 million shs
CMPX Compass Therapeutics	$2.14 +0.9%	$1.89	$0.77 ▼ $4.08	$295.93M	1.4	926,063 shs	411,152 shs
DRUG Bright Minds Biosciences	$26.00 -4.9%	$31.56	$0.93 ▼ $79.02	$183.14M	-5.32	824,988 shs	26,263 shs
MBX MBX Biosciences	$12.53 -1.5%	$9.38	$4.81 ▼ $27.50	$418.80M	N/A	250,891 shs	177,747 shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CABA Cabaletta Bio	-2.09%	+6.86%	+41.67%	+3.60%	-81.39%
CMPX Compass Therapeutics	+0.94%	+2.39%	+15.05%	-26.21%	+45.58%
DRUG Bright Minds Biosciences	-4.94%	-10.38%	-15.31%	-30.18%	+2,160.87%
MBX MBX Biosciences	-1.49%	+3.13%	+19.45%	+30.52%	+1,252,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CABA Cabaletta Bio	3.139 of 5 stars	4.5	3.0	2.5	0.8	0.6
CMPX Compass Therapeutics	4.0402 of 5 stars	4.6	3.0	3.4	5.0	0.0
DRUG Bright Minds Biosciences	3.1002 of 5 stars	3.6	5.0	2.5	2.5	0.0
MBX MBX Biosciences	3.0489 of 5 stars	3.5	0.0	3.5	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CABA Cabaletta Bio	3.00	Buy	$20.33	987.34% Upside
CMPX Compass Therapeutics	3.11	Buy	$13.13	513.32% Upside
DRUG Bright Minds Biosciences	3.25	Buy	$83.25	220.19% Upside
MBX MBX Biosciences	3.00	Buy	$37.50	199.28% Upside

Current Analyst Ratings Breakdown

Latest CABA, MBX, CMPX, and DRUG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/21/2025	DRUG Bright Minds Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/16/2025	CABA Cabaletta Bio	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $13.00
5/15/2025	CABA Cabaletta Bio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$23.00 ➝ $25.00
5/13/2025	DRUG Bright Minds Biosciences	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/13/2025	DRUG Bright Minds Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/13/2025	DRUG Bright Minds Biosciences	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/9/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00
5/7/2025	DRUG Bright Minds Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$80.00
4/28/2025	CMPX Compass Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00
4/22/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/21/2025	CMPX Compass Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $24.00

(Data available from 5/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	$5.51 per share	N/A
CMPX Compass Therapeutics	$850K	348.15	N/A	N/A	$1.17 per share	1.83
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	$5.86 per share	N/A
MBX MBX Biosciences	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CABA Cabaletta Bio	-$67.68M	-$2.54	N/A	N/A	N/A	N/A	-50.10%	-45.49%	8/14/2025 (Estimated)
CMPX Compass Therapeutics	-$42.49M	-$0.41	N/A	N/A	N/A	N/A	-32.37%	-30.67%	8/11/2025 (Estimated)
DRUG Bright Minds Biosciences	-$2.06M	-$0.36	N/A	N/A	N/A	N/A	-5.85%	-5.68%	8/13/2025 (Estimated)
MBX MBX Biosciences	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A

Latest CABA, MBX, CMPX, and DRUG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/21/2025	Q1 2025	CABA Cabaletta Bio	-$0.67	-$0.71	-$0.04	-$0.71	N/A	N/A
5/15/2025	Q2 2025	DRUG Bright Minds Biosciences	-$0.39	-$0.29	+$0.10	-$0.29	N/A	N/A
5/8/2025	Q1 2025	CMPX Compass Therapeutics	-$0.12	-$0.12	N/A	-$0.12	N/A	N/A
3/31/2025	Q4 2024	CABA Cabaletta Bio	-$0.65	-$0.65	N/A	-$0.65	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	N/A
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	N/A
MBX MBX Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CABA Cabaletta Bio	N/A	8.11	8.11
CMPX Compass Therapeutics	N/A	31.84	31.84
DRUG Bright Minds Biosciences	N/A	126.01	11.31
MBX MBX Biosciences	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CABA Cabaletta Bio	N/A
CMPX Compass Therapeutics	68.43%
DRUG Bright Minds Biosciences	40.52%
MBX MBX Biosciences	N/A

Insider Ownership

Company	Insider Ownership
CABA Cabaletta Bio	11.25%
CMPX Compass Therapeutics	29.80%
DRUG Bright Minds Biosciences	42.66%
MBX MBX Biosciences	52.19%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CABA Cabaletta Bio	50	50.74 million	44.05 million	Optionable
CMPX Compass Therapeutics	20	138.28 million	98.38 million	Not Optionable
DRUG Bright Minds Biosciences	N/A	7.04 million	4.04 million	Not Optionable
MBX MBX Biosciences	36	33.42 million	N/A	N/A

CABA, MBX, CMPX, and DRUG Headlines

Recent News About These Companies

MBX Biosciences, Inc. (NYSE:MBX) Given Consensus Rating of "Buy" by Brokerages

May 31 at 1:09 AM | marketbeat.com

MBX Biosciences, Inc. (NYSE:MBX) Given Average Recommendation of "Buy" by Analysts

May 30 at 1:11 AM | americanbankingnews.com

MBX Biosciences, Inc. (NYSE:MBX) Shares Sold by Millennium Management LLC

May 29 at 3:38 AM | marketbeat.com

Northern Trust Corp Invests $1.67 Million in MBX Biosciences, Inc. (NYSE:MBX)

May 28 at 3:08 AM | marketbeat.com

Woodline Partners LP Buys 89,046 Shares of MBX Biosciences, Inc. (NYSE:MBX)

May 25, 2025 | marketbeat.com

Citadel Advisors LLC Grows Stock Holdings in MBX Biosciences, Inc. (NYSE:MBX)

May 21, 2025 | marketbeat.com

MBX Biosciences to Participate in June Investor Conferences

May 20, 2025 | globenewswire.com

Parkman Healthcare Partners LLC Purchases New Shares in MBX Biosciences, Inc. (NYSE:MBX)

May 16, 2025 | marketbeat.com

MBX Biosciences, Inc.: Strong Buy Rating Amid Promising Phase II Data and Robust Financial Position

May 13, 2025 | tipranks.com

MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 12, 2025 | globenewswire.com

Driehaus Capital Management LLC Acquires 600,438 Shares of MBX Biosciences, Inc. (NYSE:MBX)

May 11, 2025 | marketbeat.com

FESM's Underlying Holdings Could Mean 34% Gain Potential

May 10, 2025 | nasdaq.com

MBX Biosciences, Inc. (NYSE:MBX) Stake Lessened by Alyeska Investment Group L.P.

May 9, 2025 | marketbeat.com

Schonfeld Strategic Advisors LLC Purchases New Position in MBX Biosciences, Inc. (NYSE:MBX)

May 9, 2025 | marketbeat.com

MBX Biosciences, Inc. (NYSE:MBX) Receives Consensus Rating of "Buy" from Analysts

May 6, 2025 | marketbeat.com

MBX Biosciences, Inc. (NYSE:MBX) Shares Sold by Price T Rowe Associates Inc. MD

May 4, 2025 | marketbeat.com

Companies Like MBX Biosciences (NASDAQ:MBX) Are In A Position To Invest In Growth

April 23, 2025 | finance.yahoo.com

MBX Biosciences to Participate in Citizens and RBC May Investor Conferences

April 22, 2025 | globenewswire.com

Ascendis Pharma initiated with an Outperform at RBC Capital

April 16, 2025 | markets.businessinsider.com

JMP Securities Initiates Coverage of MBX Biosciences (MBX) with Market Outperform Recommendation

April 11, 2025 | msn.com

Ora H. Pescovitz Buys 7,693 Shares of MBX Biosciences, Inc. (NYSE:MBX) Stock

April 11, 2025 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CABA, MBX, CMPX, and DRUG Company Descriptions

Cabaletta Bio NASDAQ:CABA

$1.87 -0.04 (-2.09%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$1.86 -0.01 (-0.27%)

As of 05/30/2025 07:51 PM Eastern

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Compass Therapeutics NASDAQ:CMPX

$2.14 +0.02 (+0.94%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$2.12 -0.02 (-0.93%)

As of 05/30/2025 07:28 PM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Bright Minds Biosciences NASDAQ:DRUG

$26.00 -1.35 (-4.94%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$27.00 +1.00 (+3.85%)

As of 05/30/2025 07:52 PM Eastern

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

MBX Biosciences NYSE:MBX

$12.53 -0.19 (-1.49%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$12.42 -0.11 (-0.88%)

As of 05/30/2025 04:04 PM Eastern

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time